🚀 VC round data is live in beta, check it out!
WAVE Life Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for WAVE Life Sciences and similar public comparables like Apellis Pharmaceuticals, Buchang Pharma, Travere Therapeutics, SK Bioscience and more.
WAVE Life Sciences Overview
About WAVE Life Sciences
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease.
Founded
2012
HQ
Employees
288
Website
Sectors
Financials (LTM)
EV
$2B
WAVE Life Sciences Financials
WAVE Life Sciences reported last 12-month revenue of $42M and negative EBITDA of ($220M).
In the same LTM period, WAVE Life Sciences generated $40M in gross profit, ($220M) in EBITDA losses, and had net loss of ($216M).
Revenue (LTM)
WAVE Life Sciences P&L
In the most recent fiscal year, WAVE Life Sciences reported revenue of $43M and EBITDA of ($207M).
WAVE Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $42M | XXX | $43M | XXX | XXX | XXX |
| Gross Profit | $40M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($220M) | XXX | ($207M) | XXX | XXX | XXX |
| EBITDA Margin | (530%) | XXX | (483%) | XXX | XXX | XXX |
| EBIT Margin | (546%) | XXX | (503%) | XXX | XXX | XXX |
| Net Profit | ($216M) | XXX | ($204M) | XXX | XXX | XXX |
| Net Margin | (520%) | XXX | (478%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
WAVE Life Sciences Stock Performance
WAVE Life Sciences has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
WAVE Life Sciences' stock price is $13.71.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | 0.0% | XXX | XXX | XXX | $-1.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialWAVE Life Sciences Valuation Multiples
WAVE Life Sciences trades at 48.1x EV/Revenue multiple, and (9.1x) EV/EBITDA.
EV / Revenue (LTM)
WAVE Life Sciences Financial Valuation Multiples
As of March 21, 2026, WAVE Life Sciences has market cap of $3B and EV of $2B.
Equity research analysts estimate WAVE Life Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
WAVE Life Sciences has a P/E ratio of (12.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 48.1x | XXX | 46.7x | XXX | XXX | XXX |
| EV/EBITDA | (9.1x) | XXX | (9.7x) | XXX | XXX | XXX |
| EV/EBIT | (8.8x) | XXX | (9.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 50.1x | XXX | — | XXX | XXX | XXX |
| P/E | (12.0x) | XXX | (12.6x) | XXX | XXX | XXX |
| EV/FCF | (10.3x) | XXX | (10.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified WAVE Life Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
WAVE Life Sciences Margins & Growth Rates
WAVE Life Sciences' revenue in the last 12 month grew by 5%.
WAVE Life Sciences' revenue per employee in the last FY averaged $0.1M.
WAVE Life Sciences' rule of 40 is (524%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
WAVE Life Sciences' rule of X is (517%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
WAVE Life Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | (13%) | XXX | XXX | XXX |
| EBITDA Margin | (530%) | XXX | (483%) | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (524%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (517%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 185% | XXX | 176% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 457% | XXX | 428% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 604% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
WAVE Life Sciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Apellis Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Buchang Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Travere Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SK Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinocelltech Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
WAVE Life Sciences M&A Activity
WAVE Life Sciences acquired XXX companies to date.
Last acquisition by WAVE Life Sciences was on XXXXXXXX, XXXXX. WAVE Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by WAVE Life Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialWAVE Life Sciences Investment Activity
WAVE Life Sciences invested in XXX companies to date.
WAVE Life Sciences made its latest investment on XXXXXXXX, XXXXX. WAVE Life Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by WAVE Life Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout WAVE Life Sciences
| When was WAVE Life Sciences founded? | WAVE Life Sciences was founded in 2012. |
| Where is WAVE Life Sciences headquartered? | WAVE Life Sciences is headquartered in Singapore. |
| How many employees does WAVE Life Sciences have? | As of today, WAVE Life Sciences has over 288 employees. |
| Who is the CEO of WAVE Life Sciences? | WAVE Life Sciences' CEO is Paul B. Bolno. |
| Is WAVE Life Sciences publicly listed? | Yes, WAVE Life Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of WAVE Life Sciences? | WAVE Life Sciences trades under WVE ticker. |
| When did WAVE Life Sciences go public? | WAVE Life Sciences went public in 2015. |
| Who are competitors of WAVE Life Sciences? | WAVE Life Sciences main competitors are Apellis Pharmaceuticals, Buchang Pharma, Travere Therapeutics, SK Bioscience. |
| What is the current market cap of WAVE Life Sciences? | WAVE Life Sciences' current market cap is $3B. |
| What is the current revenue of WAVE Life Sciences? | WAVE Life Sciences' last 12 months revenue is $42M. |
| What is the current revenue growth of WAVE Life Sciences? | WAVE Life Sciences revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of WAVE Life Sciences? | Current revenue multiple of WAVE Life Sciences is 48.1x. |
| Is WAVE Life Sciences profitable? | No, WAVE Life Sciences is not profitable. |
| What is the current EBITDA of WAVE Life Sciences? | WAVE Life Sciences has negative EBITDA and is not profitable. |
| What is WAVE Life Sciences' EBITDA margin? | WAVE Life Sciences' last 12 months EBITDA margin is (530%). |
| What is the current EV/EBITDA multiple of WAVE Life Sciences? | Current EBITDA multiple of WAVE Life Sciences is (9.1x). |
| What is the current FCF of WAVE Life Sciences? | WAVE Life Sciences' last 12 months FCF is ($195M). |
| What is WAVE Life Sciences' FCF margin? | WAVE Life Sciences' last 12 months FCF margin is (469%). |
| What is the current EV/FCF multiple of WAVE Life Sciences? | Current FCF multiple of WAVE Life Sciences is (10.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.